Study: Brilinta shows strength in reducing heart risks

01/14/2010 | Bloomberg Businessweek

AstraZeneca's Brilinta lowered the risk of a second heart attack and death without increasing the chance of bleeding in a trial, funded by the drug firm, involving more than 13,000 patients with acute coronary syndrome. The drug could prove to be a good alternative to Plavix, which has shown to raise the risk of bleeding, a cardiologist said.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA